Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3326
Eltek
ELTK
$51.6M
| $59K | ﹤0.01% |
+14,880
| New | +$59.1K |
2020 Q2
0 quarters
|
|
|
HYPD
3327
Hyperion DeFi Inc
HYPD
$52.1M
| $59K | ﹤0.01% |
+260
| New | +$64.4K |
2020 Q2
0 quarters
|
|
3328
Koss Corp
KOSS
$36.6M
| $59K | ﹤0.01% |
43,401
+13,905
| +47% | +$17K |
2014 Q2
24 quarters
|
|
|
ADIL
3329
Adial Pharmaceuticals
ADIL
$11.8M
| $58K | ﹤0.01% |
+67
| New | +$60.5K |
2020 Q2
0 quarters
|
|
|
JXG
3330
JX Luxventure
JXG
$85.6M
| $58K | ﹤0.01% |
40
+21
| +111% | +$23.4K |
2020 Q1
1 quarter
|
|
|
STRR
3331
DELISTED
Star Equity Holdings
STRR
| $57K | ﹤0.01% |
4,058
-14,004
| -78% | -$198K |
2013 Q2
28 quarters
|
|
|
XELA
3332
DELISTED
Exela Technologies, Inc. Common Stock
XELA
| $57K | ﹤0.01% |
+9
| New | +$36.3K |
2020 Q2
0 quarters
|
|
3333
Xcel Brands
XELB
$3.94M
| $55K | ﹤0.01% |
6,120
+2,815
| +85% | +$22.4K |
2018 Q4
6 quarters
|
|
|
CYTO
3334
DELISTED
Altamira Therapeutics Ltd
CYTO
| $54K | ﹤0.01% |
+143
| New | +$53.7K |
2020 Q2
0 quarters
|
|
|
NEWA
3335
DELISTED
Newater Technology, Inc. Ordinary Shares
NEWA
| $54K | ﹤0.01% |
14,800
+500
| +3% | +$1.35K |
2019 Q2
4 quarters
|
|
3336
Jaguar Health
JAGX
$2.74M
| – | – |
0
| – | – |
2020 Q2
0 quarters
|
|
|
STAF
3337
DELISTED
Staffing 360 Solutions, Inc. Common Stock (DE)
STAF
| $53K | ﹤0.01% |
111
+34
| +44% | +$13.7K |
2019 Q2
4 quarters
|
|
|
BDR
3338
DELISTED
Blonder Tongue Laboratories Inc
BDR
| $53K | ﹤0.01% |
74,157
+4,400
| +6% | +$2.61K |
2014 Q3
23 quarters
|
|
|
PSV
3339
DELISTED
Hermitage Offshore Services Ltd.
PSV
| $53K | ﹤0.01% |
+102,680
| New | +$65K |
2020 Q2
0 quarters
|
|
|
AMBO
3340
Ambow Education Holding
AMBO
| $52K | ﹤0.01% |
2,934
+870
| +42% | +$17.6K |
2018 Q4
6 quarters
|
|
|
EDN
3341
Edenor
EDN
$886M
| $52K | ﹤0.01% |
+13,100
| New | +$46.1K |
2020 Q2
0 quarters
|
|
|
ATHX
3342
DELISTED
Athersys, Inc. Common Stock
ATHX
| $52K | ﹤0.01% |
752
-37,289
| -98% | -$2.59M |
2017 Q3
11 quarters
|
|
3343
Pyxis Tankers
PXS
$80.7M
| $51K | ﹤0.01% |
+16,810
| New | +$61.5K |
2020 Q2
0 quarters
|
|
3344
ReTo Eco-Solutions
RETO
$3.25M
| – | – |
0
| – | – |
2019 Q1
5 quarters
|
|
3345
Universal Safety Products Inc
UUU
$15.8M
| $50K | ﹤0.01% |
62,823
+1,800
| +3% | +$1.12K |
2014 Q4
22 quarters
|
|
|
SGRP
3346
DELISTED
SPAR Group
SGRP
| $49K | ﹤0.01% |
65,200
-25,800
| -28% | -$19.6K |
2019 Q3
3 quarters
|
|
|
DXYN
3347
DELISTED
Dixie Group Inc
DXYN
| $48K | ﹤0.01% |
+52,200
| New | +$39.8K |
2020 Q2
0 quarters
|
|
|
GRIN
3348
DELISTED
Grindrod Shipping Holdings Ltd. Ordinary Shares
GRIN
| $47K | ﹤0.01% |
17,200
+1,880
| +12% | +$4.75K |
2019 Q4
2 quarters
|
|
|
WIMI
3349
WiMi Hologram Cloud
WIMI
$11.8M
| $44K | ﹤0.01% |
+1,280
| New | +$55.9K |
2020 Q2
0 quarters
|
|
|
PLG
3350
Platinum Group Metals
PLG
$166M
| $42K | ﹤0.01% |
+28,500
| New | +$42.7K |
2020 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.